Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: A retrospective study

International Journal of Antimicrobial Agents

Volumn 46, Issue 6, 2015, Pages 610-615

  Lee, Chen Hsiang ^a,b   Su, Lin Hui ^a,b   Chen, Fang Ju ^a   Tang, Ya Feng ^a   Li, Chia Chin ^a   Chien, Chun Chih ^a   Liu, Jien Wei ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Case control study; Cephamycins; Enterobacteriaceae; Mortality; Outcome; Propensity score matching

Indexed keywords

CARBAPENEM DERIVATIVE; ERTAPENEM; FLOMOXEF; IMIPENEM; MEROPENEM; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BLOOD CULTURE; CASE CONTROL STUDY; CATHETER INFECTION; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSESSMENT; DRUG EFFICACY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PATHOGENESIS; PITT BACTEREMIA SCORE; PNEUMONIA; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; TAIWAN; TREATMENT OUTCOME; UROSEPSIS; VERY ELDERLY; COMPARATIVE STUDY; DRUG EFFECTS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CARBAPENEMS; CASE-CONTROL STUDIES; CEPHALOSPORINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84949724452     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.07.020     Document Type: Article

References (24)

1. D.L. Paterson, and R.A. Bonomo Extended-spectrum β-lactamases: a clinical update Clin Microbiol Rev 18 2005 657 686
2. J.D. Pitout, and K.B. Laupland Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern Lancet Infect Dis 8 2008 159 166
3. R. Ramphal, and P.G. Ambrose Extended-spectrum β-lactamases and clinical outcomes: current data Clin Infect Dis 42 Suppl. 4 2006 S164 S172
4. M.E. Falagas, P.I. Rafaailidis, D. Kofteridis, S. Virtzili, F.C. Chelvatzoglou, V. Papaioannou, and et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study J Antimicrob Chemother 60 2007 1124 1130
5. C.H. Lee, L.H. Su, Y.F. Tang, and J.W. Liu Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates J Antimicrob Chemother 58 2006 1074 1077
6. J.D. Pitout Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices Drugs 70 2010 313 333
7. G. Kahlmeter Breakpoints for intravenously used cephalosporins in Enterobacteriaceae - EUCAST and CLSI breakpoints Clin Microbiol Infect 14 Suppl. 1 2008 S169 S174
8. A. Wong-Beringer, J. Hindler, M. Loeloff, A.M. Queenan, N. Lee, D.A. Pegues, and et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime Clin Infect Dis 34 2002 135 146
9. M.M. Levy, M.P. Fink, J.C. Marshall, E. Abraham, D. Angus, D. Cook, and et al. International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference Intensive Care Med 29 2003 530 538
10. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. Document M100-S24 2014 CLSI Wayne, PA
11. H. Grimm Interpretive criteria of antimicrobial disk susceptibility tests with flomoxef Infection 19 Suppl. 5 1991 S258 S263
12. I.L. Chen, C.H. Lee, L.H. Su, S.J. Chang, and J.W. Liu Antibiotic consumption and healthcare-associated infections caused by multidrug-resistant Gram-negative bacilli at a large medical center in Taiwan from 2002 to 2009: implicating the importance of antibiotic stewardship PLoS One 8 2013 e65621
13. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. Document M100-S20 2010 CLSI Wayne, PA
14. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
15. J.W. Chow, and V.L. Yu Combination antibiotic therapy versus monotherapy for Gram-negative bacteremia: a commentary Int J Antimicrob Agents 11 1999 7 12
16. S.H. Kim, S.B. Hong, S.C. Yun, W.I. Choi, J.J. Ahn, Y.J. Lee, and et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores Am J Respir Crit Care Med 183 2011 1207 1214
17. D. Andes, and W.A. Craig Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations Clin Microbiol Infect 11 Suppl. 6 2005 10 17
18. D. Maglio, C. Ong, M.A. Banevicious, Q. Geng, C.H. Nightingale, and D.P. Nicolau Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-β-lactamase-producing Escherichia coli at various inocula Antimicrob Agents Chemother 48 2004 1941 1947
19. J.J. Schrogie, R.O. Davies, K.C. Yeh, D. Rogers, G.I. Holmes, H. Skeggs, and et al. Bioavailability and pharmacokinetics of cefoxitin sodium J Antimicrob Chemother 4 1978 69 78
20. G.G. Zhanel, A. Denisuik, S. Vashisht, C. Yachison, H.J. Adam, and D.J. Hoban Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model J Antimicrob Chemother 69 2014 2448 2452
21. C.C. Yang, S.H. Li, F.R. Chuang, C.H. Chen, C.H. Lee, J.B. Chen, and et al. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended-spectrum β-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis BMC Infect Dis 12 2012 206
22. C.I. Kang, S.H. Kim, W.B. Park, K.D. Lee, H.B. Kim, E.C. Kim, and et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy Antimicrob Agents Chemother 48 2004 4574 4581
23. M. Tumbarello, M. Sanguinetti, E. Montuori, E.M. Trecarichi, B. Posteraro, B. Fiori, and et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment Antimicrob Agents Chemother 51 2007 1987 1994
24. C.H. Lee, L.H. Su, C.C. Li, C.C. Chien, Y.F. Tang, and J.W. Liu Bacteremia due to extended-spectrum β-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC β-lactamase (DHA-1): microbiologic and clinical implications Antimicrob Agents Chemother 54 2010 5395 5398